{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:36:34Z","timestamp":1768552594766,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T00:00:00Z","timestamp":1513123200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Mirati Therapeutics Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00280-017-3494-3","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T14:30:50Z","timestamp":1513175450000},"page":"355-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Phase I\/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors"],"prefix":"10.1007","volume":"81","author":[{"given":"Emily","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Gabriela","family":"Chiorean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nashat Y.","family":"Gabrail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Alcindor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Potvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,13]]},"reference":[{"key":"3494_CR1","unstructured":"Society AC (2016) Cancer Facts & Figs. 2016. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2016\/cancer-facts-and-figures-2016.pdf . Accessed Oct 2017"},{"issue":"6","key":"3494_CR2","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/jco.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403\u20132413. https:\/\/doi.org\/10.1200\/jco.1997.15.6.2403","journal-title":"J Clin Oncol"},{"issue":"26 Suppl","key":"3494_CR3","doi-asserted-by":"publisher","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","volume":"5","author":"M Ducreux","year":"2015","unstructured":"Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goere D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T et al. (2015) Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 5(26 Suppl):v56\u201368. https:\/\/doi.org\/10.1093\/annonc\/mdv295","journal-title":"Ann Oncol"},{"issue":"24","key":"3494_CR4","doi-asserted-by":"publisher","first-page":"7830","DOI":"10.3748\/wjg.v20.i24.7830","volume":"20","author":"D Neureiter","year":"2014","unstructured":"Neureiter D, Jager T, Ocker M, Kiesslich T (2014) Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol 20(24):7830\u20137848. https:\/\/doi.org\/10.3748\/wjg.v20.i24.7830","journal-title":"World J Gastroenterol"},{"issue":"10","key":"3494_CR5","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1136\/gut.2009.180711","volume":"58","author":"P Fritsche","year":"2009","unstructured":"Fritsche P, Seidler B, Schuler S, Schnieke A, Gottlicher M, Schmid RM, Saur D, Schneider G (2009) HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 58(10):1399\u20131409. https:\/\/doi.org\/10.1136\/gut.2009.180711","journal-title":"Gut"},{"key":"3494_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12876-015-0379-y","volume":"15","author":"C Giaginis","year":"2015","unstructured":"Giaginis C, Damaskos C, Koutsounas I, Zizi-Serbetzoglou A, Tsoukalas N, Patsouris E, Kouraklis G, Theocharis S (2015) Histone deacetylase (HDAC)-1, -2, -4 and \u2013 6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients\u2019 survival. BMC Gastroenterol 15:148. https:\/\/doi.org\/10.1186\/s12876-015-0379-y","journal-title":"BMC Gastroenterol"},{"issue":"7424","key":"3494_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","volume":"491","author":"AV Biankin","year":"2012","unstructured":"Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J et al (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491(7424):399\u2013405. https:\/\/doi.org\/10.1038\/nature11547","journal-title":"Nature"},{"issue":"5897","key":"3494_CR8","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897):1801\u20131806. https:\/\/doi.org\/10.1126\/science.1164368","journal-title":"Science"},{"issue":"4","key":"3494_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/cancers8040045","volume":"8","author":"D Zeitouni","year":"2016","unstructured":"Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL (2016) KRAS mutant pancreatic cancer: no lone path to an effective treatment. Cancers (Basel) 8(4):45. https:\/\/doi.org\/10.3390\/cancers8040045","journal-title":"Cancers (Basel)"},{"issue":"7540","key":"3494_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K et al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518(7540):495\u2013501. https:\/\/doi.org\/10.1038\/nature14169","journal-title":"Nature"},{"issue":"1","key":"3494_CR11","doi-asserted-by":"publisher","first-page":"e85942","DOI":"10.1371\/journal.pone.0085942","volume":"9","author":"M Javle","year":"2014","unstructured":"Javle M, Li Y, Tan D, Dong X, Chang P, Kar S, Li D (2014) Biomarkers of TGF-beta signaling pathway and prognosis of pancreatic cancer. PLoS One 9(1):e85942. https:\/\/doi.org\/10.1371\/journal.pone.0085942","journal-title":"PLoS One"},{"issue":"11","key":"3494_CR12","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Gunther A, Nakorn TN, Siritanaratkul N et al (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15(11):1195\u20131206. https:\/\/doi.org\/10.1016\/S1470-2045(14)70440-1","journal-title":"Lancet Oncol"},{"issue":"6","key":"3494_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M et al (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30(6):631\u2013636. https:\/\/doi.org\/10.1200\/JCO.2011.37.4223","journal-title":"J Clin Oncol"},{"issue":"10","key":"3494_CR14","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10):1247\u20131252. https:\/\/doi.org\/10.1634\/theoncologist.12-10-1247","journal-title":"Oncologist"},{"issue":"23","key":"3494_CR15","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S et al (2015) Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal Phase II BELIEF (CLN-19) study. J Clin Oncol 33(23):2492\u20132499. https:\/\/doi.org\/10.1200\/JCO.2014.59.2782","journal-title":"J Clin Oncol"},{"issue":"4","key":"3494_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/1535-7163.MCT-07-2026","volume":"7","author":"M Fournel","year":"2008","unstructured":"Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF et al. (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7 (4):759\u2013768. https:\/\/doi.org\/10.1158\/1535-7163.MCT-07-2026","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"3494_CR17","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1021\/jm800251w","volume":"51","author":"N Zhou","year":"2008","unstructured":"Zhou N, Moradei O, Raeppel S, Leit S, Frechette S, Gaudette F, Paquin I, Bernstein N, Bouchain G, Vaisburg A et al (2008) Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem 51(14):4072\u20134075. https:\/\/doi.org\/10.1021\/jm800251w","journal-title":"J Med Chem"},{"issue":"4","key":"3494_CR18","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2007-10-115873","volume":"112","author":"G Garcia-Manero","year":"2008","unstructured":"Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH Jr, Rousseau C, Kalita A et al (2008) Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112(4):981\u2013989. https:\/\/doi.org\/10.1182\/blood-2007-10-115873","journal-title":"Blood"},{"issue":"4","key":"3494_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1365-2141.2009.07881.x","volume":"147","author":"KA Blum","year":"2009","unstructured":"Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S, Kassis J, Davis M, Bonfils C, Dubay M et al (2009) Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 147(4):507\u2013514. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07881.x","journal-title":"Br J Haematol"},{"issue":"13","key":"3494_CR20","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S1470-2045(11)70265-0","volume":"12","author":"A Younes","year":"2011","unstructured":"Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J et al (2011) Mocetinostat for relapsed classical Hodgkin\u2019s lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 12(13):1222\u20131228","journal-title":"Lancet Oncol"},{"issue":"4","key":"3494_CR21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/bjh.14698","volume":"178","author":"CL Batlevi","year":"2017","unstructured":"Batlevi CL, Crump M, Andreadis C, Rizzieri D, Assouline SE, Fox S, van der Jagt RHC, Copeland A, Potvin D, Chao R et al (2017) A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. Br J Haematol 178(4):434\u2013441. https:\/\/doi.org\/10.1111\/bjh.14698","journal-title":"Br J Haematol"},{"issue":"6","key":"3494_CR22","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/j.1349-7006.2011.01921.x","volume":"102","author":"V Sung","year":"2011","unstructured":"Sung V, Richard N, Brady H, Maier A, Kelter G, Heise C (2011) Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells. Cancer Sci 102(6):1201\u20131207. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.01921.x","journal-title":"Cancer Sci"},{"issue":"12","key":"3494_CR23","doi-asserted-by":"publisher","first-page":"e52095","DOI":"10.1371\/journal.pone.0052095","volume":"7","author":"G Wang","year":"2012","unstructured":"Wang G, He J, Zhao J, Yun W, Xie C, Taub JW, Azmi A, Mohammad RM, Dong Y, Kong W et al (2012) Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS One 7(12):e52095. https:\/\/doi.org\/10.1371\/journal.pone.0052095","journal-title":"PLoS One"},{"key":"3494_CR24","doi-asserted-by":"publisher","first-page":"690901","DOI":"10.5402\/2012\/690901","volume":"2012","author":"PV Licciardi","year":"2012","unstructured":"Licciardi PV, Karagiannis TC (2012) Regulation of immune responses by histone deacetylase inhibitors. ISRN Hematol 2012:690901. https:\/\/doi.org\/10.5402\/2012\/690901","journal-title":"ISRN Hematol"},{"issue":"2","key":"3494_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12026-007-0085-0","volume":"40","author":"AN Khan","year":"2008","unstructured":"Khan AN, Tomasi TB (2008) Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res 40(2):164\u2013178. https:\/\/doi.org\/10.1007\/s12026-007-0085-0","journal-title":"Immunol Res"},{"issue":"10","key":"3494_CR26","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1073\/pnas.1011037108","volume":"108","author":"AJ Christiansen","year":"2011","unstructured":"Christiansen AJ, West A, Banks KM, Haynes NM, Teng MW, Smyth MJ, Johnstone RW (2011) Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci U S A 108(10):4141\u20134146. https:\/\/doi.org\/10.1073\/pnas.1011037108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3494_CR27","doi-asserted-by":"publisher","first-page":"e30815","DOI":"10.1371\/journal.pone.0030815","volume":"7","author":"L Shen","year":"2012","unstructured":"Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, Fenstermaker R, Pili R (2012) Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One 7(1):e30815. https:\/\/doi.org\/10.1371\/journal.pone.0030815","journal-title":"PLoS One"},{"issue":"12","key":"3494_CR28","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","volume":"3","author":"DM Woods","year":"2015","unstructured":"Woods DM, Sodre AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J (2015) HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol Res 3(12):1375\u20131385. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0077-T","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"3494_CR29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"3494_CR30","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1158\/1078-0432.CCR-07-4427","volume":"14","author":"C Bonfils","year":"2008","unstructured":"Bonfils C, Kalita A, Dubay M, Siu LL, Carducci MA, Reid G, Martell RE, Besterman JM, Li Z (2008) Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res 14(11):3441\u20133449. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4427","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3494_CR31","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1200\/JCO.2007.14.5730","volume":"26","author":"LL Siu","year":"2008","unstructured":"Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, MacLean M, King S, Brown S, Reid GK et al (2008) Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 26(12):1940\u20131947. https:\/\/doi.org\/10.1200\/JCO.2007.14.5730","journal-title":"J Clin Oncol"},{"issue":"19","key":"3494_CR32","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"issue":"18","key":"3494_CR33","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Hoff Von","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"issue":"3","key":"3494_CR34","first-page":"225","volume":"9","author":"SF Jones","year":"2011","unstructured":"Jones SF, Bendell JC, Infante JR, Spigel DR, Thompson DS, Yardley DA, Greco FA, Murphy PB, Burris HA, 3rd (2011) A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors. Clin Adv Hematol Oncol 9(3):225\u2013230","journal-title":"Clin Adv Hematol Oncol"},{"issue":"6","key":"3494_CR35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3109\/07357907.2012.675382","volume":"30","author":"SF Jones","year":"2012","unstructured":"Jones SF, Infante JR, Spigel DR, Peacock NW, Thompson DS, Greco FA, McCulloch W, Burris HA, 3rd (2012) Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors. Cancer Invest 30(6):481\u2013486. https:\/\/doi.org\/10.3109\/07357907.2012.675382","journal-title":"Cancer Invest"},{"issue":"7","key":"3494_CR36","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/annonc\/mdl081","volume":"17","author":"DA Richards","year":"2006","unstructured":"Richards DA, Boehm KA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, Rosemurgy A, Grove W, Macdonald K, Gulyas S, Clark M et al (2006) Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol 17(7):1096\u20131102. https:\/\/doi.org\/10.1093\/annonc\/mdl081","journal-title":"Ann Oncol"},{"key":"3494_CR37","unstructured":"EliLilly (2017) Gemzar prescribing information. http:\/\/pi.lilly.com\/us\/gemzar.pdf . Accessed Oct 2017"},{"key":"3494_CR38","unstructured":"MedFacts.com (2017) Study of possible correlation between cystitis and gemcitabine HCl. http:\/\/mobile.medsfacts.com\/study-GEMCITABINE%20HCL-causing-CYSTITIS.php . Accessed Oct 2017"},{"issue":"4","key":"3494_CR39","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","volume":"28","author":"R Addeo","year":"2010","unstructured":"Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, Miragliuolo A, Guarrasi R, Lanna M, Cennamo G et al (2010) Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 28(4):543\u2013548. https:\/\/doi.org\/10.1200\/JCO.2008.20.8199","journal-title":"J Clin Oncol"},{"issue":"12","key":"3494_CR40","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.6004\/jnccn.2013.0172","volume":"11","author":"V Pokuri","year":"2013","unstructured":"Pokuri V, Sule N, Soofi Y, Xu B, Guru K, George S (2013) A case of unusual mast cell response with interstitial cystitis-like symptoms to neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder. J Natl Compr Canc Netw 11(12):1459\u20131463","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"3494_CR41","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1517\/13543784.2011.577737","volume":"20","author":"Y Boumber","year":"2011","unstructured":"Boumber Y, Younes A, Garcia-Manero G (2011) Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opin Investig Drugs 20(6):823\u2013829. https:\/\/doi.org\/10.1517\/13543784.2011.577737","journal-title":"Expert Opin Investig Drugs"},{"key":"3494_CR42","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1182\/blood.V114.22.4756.4756","volume":"114","author":"RE Martell","year":"2009","unstructured":"Martell RE, Garcia-Manero G, Younes A, Ewer M, Daher IN, Hunt W, Lortie K, Wilhelm J, Besterman JM (2009) Clinical development of MGCD0103, an isotype-selective HDAC inhibitor: pericarditis\/pericardial effusion in the context of overall safety and efficacy. Blood 114:4756","journal-title":"Blood"},{"issue":"16","key":"3494_CR43","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1200\/JCO.2006.09.0886","volume":"25","author":"R Herrmann","year":"2007","unstructured":"Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi B et al (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25(16):2212\u20132217. https:\/\/doi.org\/10.1200\/JCO.2006.09.0886","journal-title":"J Clin Oncol"},{"issue":"24","key":"3494_CR44","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1200\/JCO.2005.05.1490","volume":"24","author":"V Heinemann","year":"2006","unstructured":"Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B et al (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24(24):3946\u20133952. https:\/\/doi.org\/10.1200\/JCO.2005.05.1490","journal-title":"J Clin Oncol"},{"issue":"2","key":"3494_CR45","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.radonc.2016.04.013","volume":"119","author":"E Chan","year":"2016","unstructured":"Chan E, Arlinghaus LR, Cardin DB, Goff L, Berlin JD, Parikh A, Abramson RG, Yankeelov TE, Hiebert S, Merchant N et al (2016) Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiother Oncol 119(2):312\u2013318. https:\/\/doi.org\/10.1016\/j.radonc.2016.04.013","journal-title":"Radiother Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3494-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3494-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3494-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T07:33:32Z","timestamp":1603524812000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3494-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,13]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["3494"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3494-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,13]]}}}